Eric Nuermberger, MD

Eric Nuermberger, M.D. is Associate Professor of Medicine and International Health at Johns Hopkins University. He has been involved in the development of new anti-tubercular agents since 2001. His research using in vitro and animal models of tuberculosis to optimize dosing of new and existing drugs and design optimal drug combinations has informed the clinical development of moxifloxacin, rifapentine, pretomanid, bedaquiline and sutezolid and the pre-clinical development of numerous other compounds. It is funded by the National Institutes of Health, the U.S. Food and Drug Administration, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, and various pharmaceutical companies. Dr. Nuermberger is a member of the AIDS Clinical Trial Group’s TB Transformative Science Group and the Core Science Group of the TB Trials Consortium.  He is also Co-Chair of the Preclinical and Clinical Sciences Work Group of the Critical Path to TB Drug Regimens (CPTR) initiative. Dr. Nuermberger also serves as an Associate Editor of the Antimicrobial Agents and Chemotherapy and the International Journal of TB and Lung Disease.

  • Investigator, TB Transformative Science Group (Dec 2016-Nov 2018)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More